Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review.

Adam M KaseAbdel-Ghani AzzouqaSwapna KochuveettilGerardo Colon-Otero

Published in: Cancer medicine (2023)

This well-tolerated regimen shows promising activity in recurrent ovarian cancer and is a viable option for patients who are intolerant to paclitaxel or carboplatin because of allergic reactions.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
randomized controlled trial
clinical trial
squamous cell carcinoma
radiation therapy
locally advanced
study protocol
rectal cancer